Immunosuppression with Rituximab in Glomerular Diseases in Adults: Who, How and When?
Rituximab, a monoclonal antibody with the ability to bind itself to CD20, leads to a rapid depletion of B-cells (in around 24-72 hours), limiting antibody formation. The marker CD20 does not exist in any other cell type, which makes the action of rituximab specific. This antibody has been used in a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Publicações Ciência e Vida
2023-06-01
|
| Series: | Revista Portuguesa de Nefrologia e Hipertensão |
| Subjects: | |
| Online Access: | https://spnefro.pt/_doi/reference/cbe0a333-3a31-4926-a522-7e725cad311a |
| Summary: | Rituximab, a monoclonal antibody with the ability to bind itself to CD20, leads to a rapid depletion of B-cells (in around 24-72 hours), limiting antibody formation. The marker CD20 does not exist in any other cell type, which makes the action of rituximab specific.
This antibody has been used in autoimmune entities such as rheumatoid arthritis and in hematological malignancies, but recently it has
gained popularity as an important immunosuppressor in selected kidney diseases. In nephrology, this anti-CD20 antibody had its first indication in anti-neutrophil cytoplasmic antibody-associated vasculitis, but can now be used in primary membranous nephropathy, minimal change
disease, lupus nephritis and others. There is also some data that indicates rituximab might have a promising role in other glomerular diseases
in the future, but to date evidence is still lacking to recommend its widespread use.
The aim of this document is to compile the most recent scientific evidence as to when rituximab should be used in the treatment of various
glomerular diseases, and which other may come to benefit from it in the future. |
|---|---|
| ISSN: | 0872-0169 2183-1289 |